MG
DAWN

Michael Gelband’s Day One Biopharmaceuticals DAWN Stock Holding History

Michael Gelband’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,321
Closed -$366K – 1660
2025
Q4 		$366K Sell
39,321
-21,600
-35% -$180K ﹤0.01% 1262
2025
Q3 		$429K Sell
60,921
-259,296
-81% -$1.78M ﹤0.01% 1226
2025
Q2 		$2.08M Buy
320,217
+296,480
+1,249% +$2.04M 0.02% 732
2025
Q1 		$188K Sell
23,737
-191,400
-89% -$2.06M ﹤0.01% 1307
2024
Q4 		$2.73M Buy
+215,137
New +$2.99M 0.02% 606
2024
Q3 		– Sell
-14,873
Closed -$205K – 1711
2024
Q2 		$205K Sell
14,873
-82,748
-85% -$1.21M ﹤0.01% 1390
2024
Q1 		$1.61M Buy
97,621
+56,718
+139% +$849K 0.01% 789
2023
Q4 		$597K Sell
40,903
-183,706
-82% -$2.23M ﹤0.01% 983
2023
Q3 		$2.76M Buy
224,609
+37,424
+20% +$488K 0.03% 568
2023
Q2 		$2.23M Buy
+187,185
New +$2.44M 0.02% 766
2023
Q1 		– Sell
-65,929
Closed -$1.42M – 1817
2022
Q4 		$1.42M Buy
65,929
+53,026
+411% +$1.09M 0.02% 791
2022
Q3 		$258K Sell
12,903
-10,100
-44% -$215K ﹤0.01% 1563
2022
Q2 		$412K Buy
+23,003
New +$238K 0.01% 1429
2021
Q3 		– Sell
-9,372
Closed -$213K – 2219
2021
Q2 		$213K Buy
+9,372
New +$196K ﹤0.01% 1948

Other funds holding DAWN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.75B AUM 102.57% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Michael Gelband's DAWN Position: Q1 2026 in Review

Michael Gelband sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 39,321 shares — an estimated $366K sold.

Michael Gelband first reported a position in DAWN in Q2 2021 and held it in 14 quarters. The position peaked at $2.76M in Q3 2023. 207 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Michael Gelband reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 39,321 Day One Biopharmaceuticals shares in Q1 2026, an estimated $366K.
  • Michael Gelband first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 14 quarters.
  • Michael Gelband's Day One Biopharmaceuticals position peaked at $2.76M in Q3 2023.
  • 207 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.